Clinical Trials Browser

Breast Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

89 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT06607692 2026-04-14

LUPARPED

Phase 1/2 Recruiting

25 enrolled

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

Clinical Trials

Selumetinib and Olaparib in Solid Tumors

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

LUPARPED

CAPRI

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

PIPSeN

TAPUR

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

ORCHID

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

PLANET

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

RADIOLA

I-SPY

DAPA-ARMOR

PROOV

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Surgical Pembro +/- Olaparib w TMZ for rGBM

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

DOVACC

RADIOSARP

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

FAB

PETREMAC

A Dye for the Detection of Cancer of the Tongue and Mouth

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

DAPPER

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Pembro With Radiation With or Without Olaparib

Pembrolizumab Plus Olaparib in LA-HNSCC

NePtune

RAINBO-RED

ESMART

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer